China approves human testing of a potential Covid-19 vaccine developed inside insect cells.

The use of insect cells to develop proteins for the Covid-19 anti-vaccine, first implemented in China, could accelerate production on a large scale, the Chengdu city government, southwestern China.

The vaccine was developed by Sichuan Tay China University Hospital and has been approved by the National Health Product Administration for inclusion in clinical trials.

China is one of the countries participating in the global race to develop vaccines in response to the Covid-19 pandemic.

Foreign companies, including BioNTech of Germany and Inovio Pharma of the US, also partnered with local companies to test their vaccines in China.

On August 11, China's National Intellectual Property Office patented the first Covid-19 vaccine, called Ad5-nCOV, developed by the biopharmaceutical company CanSino Biologics.

Meanwhile, the National Pharmaceutical Corporation of China (Sinopharm) also said it is developing a Covid-19 vaccine that could be widely used by the end of this year.

This candidate has entered the final stage of human trials in the United Arab Emirates to evaluate the effectiveness of the final approval steps.